Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis

Journal of the Neurological Sciences

Volumn 376, Issue , 2017, Pages 242-254

  Bagyinszky, Eva ^a   Giau, Vo Van ^a   Shim, Kyuhwan ^a   Suk, Kyoungho ^b   An, Seong Soo A ^a   Kim, SungYun ^c  

^a Gachon University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Alzheimer's disease; Diagnosis; Inflammation; Neurodegeneration; Neuroprotection; Oxidative stress

Indexed keywords

ALPHA CHEMOKINE; ALPHA INTERFERON; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL ADHESION MOLECULE; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; CX3C CHEMOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; LACTOFERRIN; LYMPHOTOXIN; PENTRAXIN; PHOSPHOLIPASE A; PLATELET DERIVED GROWTH FACTOR; PROCALCITONIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALZHEIMER DISEASE; ASTROCYTE; BODY FLUID; BRAIN; CELLULAR IMMUNITY; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; DISEASE EXACERBATION; IMMUNOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE PROGRESSION; HUMANS;

EID: 85016398959     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2017.03.031     Document Type: Review

References (248)

1. [1] Thal, L.J., et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20 (2006), 6–15.
2. [2] Frank, R.A., et al. Biological markers for therapeutic trials in Alzheimer's disease: proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24 (2003), 521–536.
3. [3] Grammas, P., Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J. Neuroinflammation, 2011, 26, 10.1186/1742-2094-8-26.
4. [4] Altman, R., Rutledge, J.C., The vascular contribution to Alzheimer's disease. Clin. Sci. (Lond.) 119 (2010), 407–421.
5. [5] Elenkov, I.J., et al. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immnune system. Pharmacol. Rev. 52 (2000), 595–638.
6. [6] Reyes-García, M.G., García-Tamayo, F., A neurotransmitter system that regulates macrophage pro-inflammatory functions. J. Neuroimmunol. 216 (2009), 20–31, 10.1016/j.jneuroim.2009.06.024.
7. [7] Szelényi, J., Cytokines and the central nervous system. Brain Res. Bull. 54 (2001), 329–338.
8. [8] Regen, F., Hellmann-Regen, J., Costantini, E., Reale, M., Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation. Curr Alzheimer Res., 2017 Feb 3, 10.2174/1567205014666170203141717.
9. [9] Casoli, T., et al. Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets. Biogerontology 11 (2011), 627–633, 10.1007/s10522-010-9281-8.
10. [10] Grammas, P., Martinez, J., Miller, B., Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med., 13, 2011, e19, 10.1017/S1462399411001918.
11. [11] Mrak, R.E., Neuropathology and the neuroinflammation idea. J. Alzheimers Dis. 18 (2009), 473–481, 10.3233/JAD-2009-1158.
12. [12] van Exel, E., et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch. Gen. Psychiatry 66 (2009), 1263–1270, 10.1001/archgenpsychiatry.2009.146.
13. [13] McNaull, B.B., Todd, S., McGuinness, B., Passmore, A.P., Inflammation and anti-inflammatory strategies for Alzheimer's disease–a mini-review. Gerontology 56 (2010), 3–14.
14. [14] Ramberg, V., et al. The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide. J. Neuroinflammation, 8, 2011, 10.1186/1742-2094-8-34.
15. [15] Pan, M.H., Lai, C.S., Ho, C.T., Anti-inflammatory activity of natural dietary flavonoids. Food Funct. 1 (2010), 15–31, 10.1039/c0fo00103a.
16. [16] Heneka, M.T., et al. Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm. 117 (2010), 919–947, 10.1007/s00702-010-0438-z.
17. [17] Calabrese, V., et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233 (2005), 145–162.
18. [18] Morales, I., Farías, G.A., Cortes, N., Maccioni, R.B., Neuroinflammation and neurodegeneration. Update on Dementia, 2016, InTech, 10.5772/64545 (ISBN 978-953-51-2655-3).
19. [19] Morales, I., Guzmán-Martínez, L., Cerda-Troncoso, C., Farías, G.A., Maccioni, R.B., Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell. Neurosci., 8, 2014, 112, 10.3389/fncel.2014.00112 (eCollection 2014).
20. [20] Venneti, S., Wiley, C.A., Kofler, J., Imaging microglial activation duringneuroinflammation and Alzheimer's disease. J. NeuroImmune Pharmacol. 4 (2009), 227–243, 10.1007/s11481-008-9142-2.
21. [21] Lai, A.Y., McLaurin, J., Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 7 (2012), 165–176.
22. [22] Cai, Z., Hussain, M.D., Yan, L.J., Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int. J. Neurosci. 124 (2014), 307–321, 10.3109/00207454.2013.833510.
23. [23] Hanisch, U.K., Kettenmann, H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007), 1387–1394.
24. [24] Dheen, S.T., Kaur, C., Ling, E.A., Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 14 (2007), 1189–1197.
25. [25] Mandrekar-Colucci, S., Landreth, G.E., Microglia and inflammation in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 9 (2010), 156–167.
26. [26] Simard, A.R., Soulet, D., Gowing, G., Julien, J.P., Rivest, S., Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49 (2006), 489–502.
27. [27] London, A., Cohen, M., Schwartz, M., Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front. Cell. Neurosci., 7, 2013, 34, 10.3389/fncel.2013.00034 (eCollection 2013).
28. [28] Malm, T., Koistinaho, M., Muona, A., Magga, J., Koistinaho, J., The role and therapeutic potential of monocytic cells in Alzheimer's disease. Glia 58:8 (2010), 889–900, 10.1002/glia.20973.
29. [29] Hohsfield, L.A., Humpel, C., Migration of blood cells to β-amyloid plaques in Alzheimer's disease. Exp. Gerontol. 65 (2015), 8–15, 10.1016/j.exger.2015.03.002.
30. [30] Agostinho, P., Cunha, R.A., Oliveira, C., Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 16 (2010), 2766–2778.
31. [31] Avila-Muñoz, E., Arias, C., When astrocytes become harmful: functional and inflammatory responses that contribute to Alzheimer's disease. Ageing Res. Rev. 18 (2014), 29–40, 10.1016/j.arr.2014.07.004.
32. [32] Söllvander, et al. Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol. Neurodegener., 11, 2016, 38, 10.1186/s13024-016-0098-z.
33. [33] Lasagna-Reeves, C.A., Kayed, R., Astrocytes contain amyloid-β annular protofibrils in Alzheimer's disease brains. FEBS Lett. 585 (2011), 3052–3057, 10.1016/j.febslet.2011.08.027.
34. [34] Olson, L., Humpel, C., Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp. Gerontol. 45 (2010), 41–46, 10.1016/j.exger.2009.10.011.
35. [35] Mowjoon, M.M., Agbinya, J.I., Chaczko, Z., Replicating cytokines in modelling signal exchange between nodes in wireless mesh networks. Proceedings of the International MultiConference of Engineers and Computer Scientists 2009, vol. I, 2009 (ISBN: 978-988-17012-2-0).
36. [36] Lemere, C.A., A beneficial role for IL-1β in Alzheimer disease?. J. Clin. Invest. 117 (2007), 1483–1485.
37. [37] Elmslie, R.E., et al. Interleukins: biological properties and therapeutic potential. J. Vet. Intern. Med. 5 (1991), 5283–5293.
38. [38] Schuitemaker, A., et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging 30 (2009), 1885–1889, 10.1016/j.neurobiolaging.2008.01.014.
39. [39] Kaplin, A., et al. IL-6 release by LPS-stimulated peripheral blood mononuclear cells as a potential biomarker in Alzheimer's disease. Int. Psychogeriatr. 21 (2009), 413–414, 10.1017/S1041610208008107.
40. [40] Arosio, B., et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol. Aging 25 (2004), 1009–1015.
41. [41] Mansoori, N., et al. IL-6-174 G/C and ApoE gene polymorphisms in Alzheimer's and vascular dementia patients attending the cognitive disorder clinic of the All India Institute of Medical Sciences, New Delhi. Dement. Geriatr. Cogn. Disord. 30 (2010), 461–468, 10.1159/000321666.
42. [42] Angelis, P., et al. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. Neurosci. Lett. 244 (1998), 106–108.
43. [43] Hampel, H., et al. Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur. Arch. Psychiatry Clin. Neurosci. 255 (2006), 269–278.
44. [44] Maedler, K., et al. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb. Exp. Pharmacol. 2011 (2011), 257–278, 10.1007/978-3-642-17214-4_11.
45. [45] Bagyinszky, E., Youn, Y.C., An, S.S., Kim, S.Y., Characterization of inflammatory biomarkers and candidates for diagnosis of Alzheimer's disease. BioChip J. 8 (2014), 155–162.
46. [46] Shaftel, S.S., et al. Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 117 (2007), 1595–1604.
47. [47] Parajuli, B., Sonobe, Y., Horiuchi, H., Takeuchi, H., Mizuno, T., Suzumura, A., Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer's disease. Cell Death Dis., 4, 2013, e975, 10.1038/cddis.2013.503.
48. [48] Franciosi, S., et al. IL-8 enhancement of amyloid-beta (Abeta 1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J. Neuroimmunol. 159 (2005), 66–74.
49. [49] Luheshi, N.M., et al. Nuclear retention of IL-1 alpha by necrotic cells: a mechanism to dampen sterile inflammation. Eur. J. Immunol. 39 (2009), 2973–2980, 10.1002/eji.200939712.
50. [50] Grimaldi, L.M., et al. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann. Neurol. 47 (2000), 361–365.
51. [51] Wang, H.K., et al. Interleukin-1alpha and -1beta promoter polymorphisms in Taiwanese patients with dementia. Dement. Geriatr. Cogn. Disord. 24 (2007), 104–110.
52. [52] Saresella, M., et al. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease. Brain Behav. Immun. 25 (2011), 539–547, 10.1016/j.bbi.2010.12.004.
53. + natural regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 12885–12890, 10.1073/pnas.0812530106.
54. [54] Pappu, R., et al. The IL-17 family cytokines in immunity and disease. J. Clin. Immunol. 30 (2010), 185–195, 10.1007/s10875-010-9369-6.
55. [55] Yin, Y., et al. Hypoxia enhances stimulating effect of amyloid beta peptide (25–35) for interleukin 17 and T helper lymphocyte subtype 17 upregulation in cultured peripheral blood mononuclear cells. Microbiol. Immunol. 53 (2009), 281–286, 10.1111/j.1348-0421.2009.00120.x.
56. [56] Jin, J.J., et al. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation, 5, 2008, 23, 10.1186/1742-2094-5-23.
57. [57] Ma, X., et al. IL-17 enhancement of the IL-6 signaling cascade in astrocytes. J. Immunol. 184 (2010), 4898–4906, 10.4049/jimmunol.1000142.
58. [58] Zhang, J., Ke, K.F., Liu, Z., Qiu, Y.H., Peng, Y.P., Th17 cell-mediated neuroinflammation is involved in neurodegeneration of aβ1–42-induced Alzheimer's disease model rats. PLoS One, 8, 2013, e75786, 10.1371/journal.pone.0075786.
59. [59] Eini, H., et al. Association between renal injury and reduced interleukin-15 and interleukin-15 receptor levels in acute kidney injury. J. Interf. Cytokine Res. 30 (2010), 1–8, 10.1089/jir.2009.0005.
60. [60] Rentzos, M., et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J. Geriatr. Psychiatry Neurol. 19 (2006), 114–117.
61. [61] Bishnoi, R.J., Palmer, R.F., Royall, D.R., Serum interleukin (IL)-15 as a biomarker of Alzheimer's disease. PLoS One, 10(2), 2015, e0117282, 10.1371/journal.pone.0117282.
62. [62] Cruikshank, W.W., Kornfeld, H., Center, D.M., Interleukin-16. J. Leukoc. Biol. 67 (2000), 757–766.
63. [63] Cruikshank, W.W., Kornfeld, H., Center, D.M., Signaling and functional properties of interleukin-16. Int. Rev. Immunol. 16 (1998), 523–540.
64. [64] Di Rosa, M., et al. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur. J. Neurosci. 23 (2006), 2648–2656.
65. [65] Momeni, P., Ferrarri, R., Genetic and blood biomarkers of Alzheimer's disease. Open Nucl. Med. J. 2 (2010), 12–24.
66. [66] Chehimi, J., et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179 (1994), 1361–1366.
67. [67] Rentzos, M., et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J. Neurol. Sci. 249 (2006), 110–114, 10.1016/j.jns.2006.05.063.
68. [68] Yu, J.T., et al. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer's disease. Brain Res. 1253 (2009), 169–175, 10.1016/j.brainres.2008.11.083.
69. [69] Sutinen, E.M., Pirttilä, T., Anderson, G., Salminen, A., Ojala, J.O., Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells. J. Neuroinflammation, 9, 2012, 199, 10.1186/1742-2094-9-199.
70. [70] Dinarello, C.A., Interleukin-18. Methods 19 (1999), 121–132, 10.1006/meth.1999.0837.
71. [71] Wu, Z., et al. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed. Pharmacother. 65:5 (2011), 339–3344, 10.1016/j.biopha.2011.04.013.
72. [72] Meda, L., et al. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid [25–35]. J. Neuroimmunol. 93 (1999), 45–52.
73. [73] Tarkowski, E., et al. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12 (2001), 314–317, 10.1159/000051276.
74. [74] Martinez-Nunez, R.T., Louafi, F., Sanchez-Elsner, T., The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J. Biol. Chem. 286 (2011), 1786–1794.
75. [75] Szczepanik, A.M., et al. IL-4, IL-10 and IL-13 modulate A beta(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 113 (2001), 49–62.
76. [76] Cavusoglu, E., et al. Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. Am. J. Med. 124 (2011), 724–730, 10.1016/j.amjmed.2011.02.040.
77. [77] Heeschen, C., et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107 (2003), 2109–2114, 10.1161/01.CIR.0000065232.57371.25.
78. [78] Angelopoulos, P., et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 118 (2008), 1659–1672, 10.1080/00207450701392068.
79. [79] Magaki, S., et al. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol. 42 (2007), 233–240, 10.1016/j.exger.2006.09.015.
80. [80] Guillot-Sestier, M.V., Doty, K.R., Gate, D., Rodriguez, J. Jr., Leung, B.P., Rezai-Zadeh, K., Town, T., Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85 (2015), 534–548, 10.1016/j.neuron.2014.12.068.
81. [81] Derecki, N.C., et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J. Exp. Med. 207 (2010), 1067–1080, 10.1084/jem.20091419.
82. [82] Park, K.W., Baik, H.H., Jin, B.K., Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Curr. Aging Sci. 1 (2008), 192–201.
83. [83] Shimizu, E., et al. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1–42) by rat primary type 2 microglia. J. Immunol. 181 (2008), 6503–6513.
84. [84] Kiyota, T., Ingraham, K.L., Jacobsen, M.T., Xiong, H., Ikezu, T., FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), E1339–E1348, 10.1073/pnas.1102349108.
85. [85] Chakrabarty, P., et al. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol. Neurodegener., 7, 2012, 36, 10.1186/1750-1326-7-36.
86. [86] Le Page, C., et al. Interferon activation and innate immunity. Rev. Immunogenet. 2 (2000), 374–386.
87. [87] Sas, A.R., et al. Interferon-alpha causes neuronal dysfunction in encephalitis. J. Neurosci. 29 (2009), 3948–3955, 10.1523/JNEUROSCI.5595-08.2009.
88. [88] Boutros, T., Croze, E., Yong, V.W., Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 69 (1997), 939–946.
89. [89] Grimaldi, L.M., et al. A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. J. Neuroinflammation, 11, 2014, 30, 10.1186/1742-2094-11-30.
90. [90] Taylor, J.M., Minter, M.R., Newman, A.G., Zhang, M., Adlard, P.A., Crack, P.J., Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiol. Aging 35 (2014), 1012–1023, 10.1016/j.neurobiolaging.2013.10.089.
91. [91] Belkhelfa, M., et al. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J. Interf. Cytokine Res. 34 (2014), 839–847, 10.1089/jir.2013.0085.
92. [92] Chakrabarty, P., et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J. Immunol. 184 (2010), 5333–5343, 10.4049/jimmunol.0903382.
93. [93] Baron, R., et al. IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease. FASEB J. 22 (2008), 2843–2852, 10.1096/fj.08-105866.
94. [94] Mastrangelo, M.A., Sudol, K.L., Narrow, W.C., Bowers, W.J., Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am. J. Pathol. 175 (2009), 2076–2088, 10.2353/ajpath.2009.090059.
95. [95] Tobinick, E., Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs 23 (2009), 713–725, 10.2165/11310810-000000000-00000.
96. [96] Varfolomeev, E.E., Ashkenazi, A., Tumor necrosis factor: an apoptosis JuNKie?. Cell 116 (2004), 491–497.
97. [97] Hsiao, H.Y., et al. TNF-alpha/IFN-gamma-induced iNOS expression increased by prostaglandin E2 in rat primary astrocytes via EP2-evoked cAMP/PKA and intracellular calcium signaling. Glia 55 (2007), 214–223, 10.1002/glia.20453.
98. [98] Rojo, L.E., et al. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res. 39 (2008), 1–16, 10.1016/j.arcmed.2007.10.001.
99. [99] Wang, P.H., et al. Molecular cloning, characterization and expression analysis of the tumor necrosis factor (TNF) superfamily gene, TNF receptor superfamily gene and lipopolysaccharide-induced TNF-α factor (LITAF) gene from Litopenaeus vannamei. Dev. Comp. Immunol. 36 (2012), 39–50, 10.1016/j.dci.2011.06.002.
100. [100] Perry, R.T., Collins, J.S., Wiener, H., Acton, R., Go, R.C., The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging 22 (2001), 873–883.
101. [101] Yang, L., et al. Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population. Brain Res. 1247 (2009), 178–181, 10.1016/j.brainres.2008.10.019.
102. [102] Bhaskar, K., et al. Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events. Neurobiol. Dis. 62 (2014), 273–285, 10.1016/j.nbd.2013.10.007.
103. [103] Sriskandan, S., et al. Lymphotoxin-alpha (TNF-beta) during sepsis. Cytokine 8 (1996), 933–937, 10.1006/cyto.1996.0125.
104. 2 + accumulation. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 9328–9332.
105. [105] Heller, R.A., et al. Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries. J. Biol. Chem. 265 (1990), 5708–57017.
106. [106] Cheng, X., et al. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J. Alzheimers Dis. 19 (2010), 621–630, 10.3233/JAD-2010-1253.
107. [107] Buchhave, P., et al. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol. Aging 31 (2010), 1877–1884, 10.1016/j.neurobiolaging.2008.10.012.
108. [108] Zhang, J., Peng, M., Jia, J., Plasma amyloid-β oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD. Curr. Alzheimer Res. 11 (2014), 325–331.
109. [109] Hamilton, J.A., Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8 (2008), 533–544, 10.1038/nri2356.
110. [110] Hesske, L., et al. Induction of inhibitory central nervous system-derived and stimulatory blood-derived dendritic cells suggests a dual role for granulocyte-macrophage colony-stimulating factor in central nervous system inflammation. Brain 133 (2010), 1637–1654, 10.1093/brain/awq081.
111. [111] Heinzelman, P., Priebe, M.C., Engineering superactive granulocyte macrophage colony-stimulating factor transferrin fusion proteins as orally-delivered candidate agents for treating neurodegenerative disease. Biotechnol. Prog., 2015, 10.1002/btpr.2071.
112. [112] Manczak, M., et al. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1–42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Hum. Mol. Genet. 18 (2009), 3876–3893, 10.1093/hmg/ddp331.
113. [113] Liu, W., et al. Macrophage colony-stimulating factor and its receptor signaling augment glycated albumin-induced retinal microglialinflammation in vitro. BMC Cell Biol., 12, 2011, 5, 10.1186/1471-2121-12-5.
114. [114] Laske, C., et al. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr. Alzheimer Res. 7 (2010), 409–414.
115. [115] Boissonneault, V., et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 132 (2009), 1078–1092, 10.1093/brain/awn331.
116. [116] Jiang, H., et al. Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer's disease mouse model. J. Int. Med. Res. 38 (2010), 1305–1312.
117. [117] Prakash, A., Medhi, B., Chopra, K., Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-β induced experimental model of Alzheimer's disease. Pharmacol. Biochem. Behav. 110 (2013), 46–57, 10.1016/j.pbb.2013.05.015.
118. [118] Song, S., Wang, X., Sava, V., Weeber, E.J., Sanchez-Ramos, J., In vivo administration of granulocyte colony-stimulating factor restores long-term depression in hippocampal slices prepared from transgenic APP/PS1 mice. J. Neurosci. Res. 92:8 (2014), 975–980, 10.1002/jnr.23378.
119. [119] Streit, W.J., Conde, J.R., Harrison, J.K., Chemokines and Alzheimer's disease. Neurobiol. Aging 22 (2001), 909–913.
120. [120] Azizi, G., Khannazer, N., Mirshafiey, A., The potential role of chemokines in Alzheimer's disease pathogenesis. Am. J. Alzheimers Dis. Other. Demen. 29 (2014), 415–425, 10.1177/1533317513518651.
121. [121] Liu, C., Cui, G., Zhu, M., et al. Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors. Int. J. Clin. Exp. Pathol. 7 (2014), 8342–8355.
122. [122] Galimberti, D., et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63 (2008), 538–543, 10.1001/archneur.63.4.538.
123. [123] Tripathy, D., Thirumangalakudi, L., Grammas, P., RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol. Aging 31 (2010), 8–16, 10.1016/j.neurobiolaging.2008.03.009.
124. [124] Selenica, M.L., et al. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J. Neuroinflammation, 10, 2013, 86, 10.1186/1742-2094-10-86.
125. [125] Kiyota, T., Gendelman, H.E., Weir, R.A., Higgins, E.E., Zhang, G., Jain, M., CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol. Aging 34 (2013), 1060–1068, 10.1016/j.neurobiolaging.2012.08.009.
126. [126] El Khoury, J., Toft, M., Hickman, S.E., Means, T.K., Terada, K., Geula, C., Luster, A.D., Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13 (2007), 432–438, 10.1038/nm1555/.
127. [127] Naert, G., Rivest, S., A deficiency in CCR2 + monocytes: the hidden side of Alzheimer's disease. J. Mol. Cell Biol. 5 (2013), 284–293, 10.1093/jmcb/mjt028.
128. [128] Villa, C., et al. CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration. J. Neurol. 256 (2009), 1379–1381, 10.1007/s00415-009-5138-y.
129. [129] Gourmala, N.G., et al. Localization of macrophage inflammatory protein: macrophage inflammatory proteins 1α and 1β expression in rat brain after peripheral administration of lipopolysaccharide and focal cerebral ischemia. Neuroscience 88 (1999), 1255–1266.
130. [130] Torres, et al. Decreased expression of CCL3 in monocytes and CCR5 in lymphocytes from frontotemporal dementia as compared with Alzheimer's disease patients. J. Neuropsychiatr. Clin. Neurosci. 24 (2012), E11–E12, 10.1176/appi.neuropsych.11060143.
131. [131] Cudaback, E., Yang, Y., Montine, T.J., Keene, C.D., APOE genotype-dependent modulation of astrocyte chemokine CCL3 production. Glia 63 (2015), 51–65, 10.1002/glia.22732.
132. [132] Wolpe, S.D., et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J. Exp. Med. 167 (1988), 570–581.
133. [133] Man, S.M., et al. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol. Aging 28 (2007), 485–496, 10.1016/j.neurobiolaging.2006.02.013.
134. [134] Xia, M.Q., et al. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol. 153 (1998), 31–37.
135. [135] Zhu, M., et al. Age-related brain expression and regulation of the chemokine CCL4/MIP-1β in APP/PS1 double-transgenic mice. J. Neuropathol. Exp. Neurol. 73 (2014), 362–374, 10.1097/NEN.0000000000000060.
136. [136] Pellicanò, M., et al. Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. J. Alzheimers Dis. 21 (2010), 181–192, 10.3233/JAD-2010-091714.
137. [137] Christen, U., et al. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J. Immunol. 171 (2003), 6838–6845.
138. [138] Duan, R.S., et al. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem. Res. 33 (2008), 1085–1089, 10.1007/s11064-007-9554-z.
139. [139] Sgadari, C., et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89 (1997), 2635–2643.
140. [140] Xia, M.Q., et al. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J. Neuroimmunol. 108 (2000), 227–235.
141. [141] Lee, K.S., et al. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Immunol. Lett. 121 (2008), 105–109, 10.1016/j.imlet.2008.09.004.
142. [142] Krauthausen, M., Kummer, M.P., Zimmermann, J., Reyes-Irisarri, E., Terwel, D., Bulic, B., Heneka, M.T., Müller, M., CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model. J. Clin. Invest. 125 (2015), 365–378, 10.1172/JCI66771.
143. [143] Kucia, M., et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J. Mol. Histol. 35 (2004), 233–245.
144. [144] Laske, C., et al. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support?. J. Alzheimers Dis. 15 (2008), 83–95.
145. [145] Wang, et al. Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model. Brain Res. 1459 (2012), 15–26, 10.1016/j.brainres.2012.04.011.
146. [146] Cubitt, C.L., Lausch, R.N., Oakes, J.E., Differential induction of GRO alpha gene expression in human corneal epithelial cells and keratocytes exposed to proinflammatory cytokines. Invest. Ophthalmol. Vis. Sci. 38 (1997), 1149–1158.
147. [147] Craig-Schapiro, R., et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One, 6, 2011, e18850, 10.1371/journal.pone.0018850.
148. [148] Lee, K.S., et al. Peripheral cytokines and chemokines in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 28 (2009), 281–287, 10.1159/000245156.
149. [149] Lastres-Becker, I., et al. Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain 137 (2014), 78–91, 10.1093/brain/awt323.
150. [150] Fuhrmann, M., Bittner, T., Jung, C.K., Burgold, S., Page, R.M., Mitteregger, G., Haass, C., LaFerla, F.M., Kretzschmar, H., Herms, J., Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 13 (2010), 411–413, 10.1038/nn.2511.
151. [151] Rubio-Perez, J.M., Morillas-Ruiz, J.M., A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal, 2012, 2012, 2012, 10.1100/2012/756357.
152. [152] Bodmer, S., et al. Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. Biochem. Biophys. Res. Commun. 171 (1990), 890–897.
153. [153] Chao, C.C., et al. Transforming growth factor beta in Alzheimer's disease. Clin. Diagn. Lab. Immunol. 1 (1993), 109–110.
154. [154] Bikfalvi, A., et al. Biological roles of fibroblast growth factor-2. Endocr. Rev. 18 (1997), 26–45, 10.1210/edrv.18.1.0292.
155. [155] Bellucci, C., et al. Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol. Med. 13 (2007), 542–550, 10.2119/2007-00034.
156. [156] Schindowski, K., Belarbi, K., Buée, L., Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 7 (2008), 43–56, 10.1111/j.1601-183X.2007.00378.x.
157. [157] Katsouri, L., Ashraf, A., Birch, A.M., Lee, K.K., Mirzaei, N., Sastre, M., Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiol. Aging 36 (2015), 821–831, 10.1016/j.neurobiolaging.2014.10.004.
158. [158] Tojima, H., et al. Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol. Int. 6 (2011), 620–630, 10.1007/s12072-011-9301-z.
159. [159] Shintani, Y., et al. Hepatocyte growth factor promotes an anti-inflammatory cytokine profile in human abdominal aortic aneurysm tissue. Atherosclerosis 216 (2011), 307–312, 10.1016/j.atherosclerosis.2011.02.025.
160. [160] Sharma, S., Hepatocyte growth factor in synaptic plasticity and Alzheimer's disease. Sci. World J. 10 (2010), 457–461, 10.1100/tsw.2010.49.
161. [161] Takeuchi, D., et al. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 15 (2008), 561–571, 10.1038/sj.gt.3303094.
162. [162] Calissano, P., Matrone, C., Amadoro, G., Nerve growth factor as a paradigm of neurotrophins 1related to Alzheimer's disease. Dev. Neurobiol. 70 (2010), 372–383, 10.1002/dneu.20759.
163. [163] Triaca, V., et al. NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease. Aging Cell 15 (2016), 661–672, 10.1111/acel.12473.
164. [164] Sen, A., Nelson, T.J., Alkon, D.L., ApoE4 and Aβ oligomers reduce BDNF expression via HDAC nuclear translocation. J. Neurosci. 35 (2015), 7538–7551, 10.1523/JNEUROSCI.0260-15.2015.
165. [165] Nagata, et al. Association between DNA methylation of the BDNF promoter region and clinical presentation in Alzheimer's disease. Dement. Geriatr. Cogn. Dis. Extra 5 (2015), 64–73, 10.1159/000375367.
166. [166] Masliah, E., et al. PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Neurobiol. Aging 16 (1995), 549–556.
167. [167] Sirois, M.G., Edelman, E.R., VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. Am. J. Phys. 272 (1997), 2746–2756.
168. [168] Proescholdt, M.A., et al. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J. Neuropathol. Exp. Neurol. 58 (1999), 613–627.
169. [169] Bürger, S., et al. Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the β-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice. Int. J. Dev. Neurosci. 28 (2010), 597–604, 10.1016/j.ijdevneu.2010.07.231.
170. [170] Provias, J., Jeynes, B., Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. Curr. Alzheimer Res. 8 (2011), 197–202.
171. [171] Schulte-Herbrüggen, O., Jockers-Scherübl, M.C., Hellweg, R., Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr. Alzheimer Res. 5 (2005), 38–44.
172. [172] Hochstrasser, T., et al. Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment. Exp. Gerontol. 45 (2010), 70–74, 10.1016/j.exger.2009.10.005.
173. [173] Fassbender, K., et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 8 (2004), 203–205, 10.1096/fj.03-0364fje.
174. [174] Sobel, R.A., Mitchell, M.E., Fondren, G., Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am. J. Pathol. 136 (1990), 1309–1316.
175. [175] Rentzos, M., et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J. Neurol. Sci. 228 (2005), 129–135, 10.1016/j.jns.2004.11.001.
176. [176] Iademarco, M.F., McQuillan, J.J., Dean, D.C., Vascular cell adhesion molecule 1: contrasting transcriptional control mechanisms in muscle and endothelium. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 3943–3971.
177. [177] Zuliani, G., et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia. J. Neurol. Sci. 272 (2008), 164–170, 10.1016/j.jns.2008.05.020.
178. [178] Picker, L.J., et al. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 349 (1991), 796–799, 10.1038/349796a0.
179. [179] Corsi, M.M., et al. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology 12 (2011), 451–454, 10.1007/s10522-011-9335-6.
180. [180] Kalinowska, A., Losy, J., PECAM-1, a key player in neuroinflammation. Eur. J. Neurol. 13 (2006), 1284–1290, 10.1111/j.1468-1331.2006.01640.x.
181. [181] Cooper, N.R., et al. Focal inflammation in the brain: role in Alzheimer's disease. Immunol. Res. 21 (2000), 159–165, 10.1385/IR:21:2-3:159.
182. [182] Sarma, J.V., Ward, P.A., The complement system. Cell Tissue Res. 343 (2011), 227–235, 10.1007/s00441-010-1034-0.
183. [183] Meraz-Ríos, M.A., et al. Inflammatory process in Alzheimer's disease. Front. Integr. Neurosci., 7, 2013, 59, 10.3389/fnint.2013.00059.
184. [184] Tahtouh, M., et al. Is complement good, bad, or both? New functions of the complement factors associated with inflammation mechanisms in the central nervous system. Eur. Cytokine Netw. 20 (2009), 95–100, 10.1684/ecn.2009.0157.
185. [185] Kolev, M.V., et al. Implication of complement system and its regulators in Alzheimer's disease. Curr. Neuropharmacol. 7 (2009), 1–8, 10.2174/157015909787602805.
186. [186] Gong, B., Levine, S., Barnum, S.R., Pasinetti, G.M., Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease. Curr. Alzheimer Res. 11 (2015), 637–644.
187. [187] Daborg, J., et al. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. J. Neural Transm. 119 (2012), 789–797, 10.1007/s00702-012-0797-8.
188. [188] Aiyaz, M., et al. Complement activation as a biomarker for Alzheimer's disease. Immunobiology 217 (2012), 204–215, 10.1016/j.imbio.2011.07.023.
189. [189] Ahn, H.J., et al. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 21812–21817, 10.1073/pnas.1010373107.
190. [190] Cortes-Canteli, M., et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66 (2010), 695–709, 10.1016/j.neuron.2010.05.014.
191. [191] Colley, K.J., Wolfert, R.L., Cobble, M.E., Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2 (2011), 27–38, 10.1007/s13167-011-0063-4.
192. [192] van Oijen, M., et al. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann. Neurol. 59 (2006), 139–144, 10.1002/ana.20721.
193. [193] Tselepis, A.D., Chapman, J.M., Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3 (2002), 57–68.
194. [194] Fitzpatrick, A.L., Irizarry, M.C., Cushman, M., Jenny, N.S., Chi, G.C., Koro, C., Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study. Atherosclerosis 235 (2014), 384–391, 10.1016/j.atherosclerosis.2014.04.032.
195. [195] Adibhatla, R.M., Hatcher, J.F., Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 49 (2008), 241–268, 10.1007/978-1-4020-8831-5_9.
196. [196] Alvarez, R., et al. Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 67 (1999), 733–736.
197. [197] Aliev, et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr. Med. Chem. 21 (2014), 2208–2217.
198. [198] Zhihui, Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy. Future Med. Chem. 5 (2013), 1451–1468, 10.4155/fmc.13.111.
199. [199] Joslin, G., et al. The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide. J. Clin. Invest. 90 (1992), 1150–1154, 10.1172/JCI115934.
200. [200] Smith, M.A., et al. Elastase is associated with the neurofibrillary pathology of Alzheimer disease: a putative link between proteolytic imbalance and oxidative stress. Restor. Neurol. Neurosci. 9 (1996), 213–217, 10.3233/RNN-1996-9403.
201. [201] Lecron, J.C., et al. High circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapy. Clin. Exp. Immunol. 92 (1993), 23–26.
202. [202] Soilu-Hänninen, M., et al. Expression of LIF and LIF receptor beta in Alzheimer's and Parkinson's diseases. Acta Neurol. Scand. 121 (2010), 44–50, 10.1111/j.1600-0404.2009.01179.x.
203. [203] Bacher, M., et al. The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol. Med. 16 (2010), 116–121, 10.2119/molmed.2009.00123.
204. [204] Li, et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer's disease. J. Neuroinflammation, 12, 2015, 177, 10.1186/s12974-015-0396-3.
205. [205] Bi Oh, S., Suh, N., Kim, I., Lee, J.Y., Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease. Brain Res. 1597 (2015), 159–167, 10.1016/j.brainres.2014.11.042.
206. [206] Jacobsen, J.S., et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8754–8759, 10.1073/pnas.0710823105.
207. [207] Inoue, K., Pentraxin 3. Rinsho Byori 59 (2011), 694–701.
208. [208] Ortega-Hernandez, O.D., et al. The long pentraxin 3 and its role in autoimmunity. Semin. Arthritis Rheum. 39 (2009), 38–54, 10.1016/j.semarthrit.2008.03.006.
209. [209] Yano, Y., et al. Plasma pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J. Gerontol. A Biol. Sci. Med. Sci. 65 (2010), 547–552, 10.1093/gerona/glq030.
210. [210] Nishiyama, E., et al. Serum amyloid P component level in Alzheimer's disease. Dementia 7 (1996), 256–259.
211. [211] de Haas, C.J., et al. Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS. Infect. Immun. 67 (1996), 2790–2796.
212. [212] Janciauskiene, S., et al. Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J. Biol. Chem. 270 (1995), 26041–26044.
213. [213] Kolstoe, S.E., et al. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 7619–7623, 10.1073/pnas.0902640106.
214. [214] Chambers, R.E., et al. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann. Rheum. Dis. 42 (1983), 665–667.
215. [215] Miida, T., et al. Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim. Biophys. Acta 1761 (2006), 424–443, 10.1016/j.bbalip.2006.03.013.
216. [216] Dahaba, A.A., Metzler, H., Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator?. Minerva Anestesiol. 75 (2009), 447–452.
217. [217] Ernst, A., et al. Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. J. Neuroimmunol. 189 (2007), 169–174, 10.1016/j.jneuroim.2007.07.009.
218. [218] Sacharczuk, M., et al. Lactoferrin in the central nervous system. Neurol. Neurochir. Pol. 39 (2005), 482–489.
219. [219] Sánchez, L., Calvo, M., Brock, J.H., Biological role of lactoferrin. Arch. Dis. Child. 67 (1992), 657–661.
220. [220] An, L., et al. Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer's disease. Neurosci. Lett. 452 (2009), 277–280, 10.1016/j.neulet.2009.01.071.
221. [221] Kawamata, T., et al. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am. J. Pathol. 142 (1993), 1574–1585.
222. [222] Lukacs, N.W., et al. The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonary mast cell activation. Blood 87 (1996), 2262–2268.
223. [223] Laske, C., et al. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J. Alzheimers Dis. 15 (2008), 451–460.
224. [224] Leyhe, T., et al. Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int. J. Neuropsychopharmacol. 12 (2009), 1319–13126, 10.1017/S1461145709990216.
225. [225] Luo, J., Grammas, P., Endothelin-1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective. J. Alzheimers Dis. 21 (2010), 887–896, 10.3233/JAD-2010-091486.
226. [226] Yoshizawa, T., et al. Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type. Neuropeptides 22 (1992), 85–88.
227. [227] Murr, C., et al. Neopterin as a marker for immune system activation. Curr. Drug Metab. 3 (2002), 175–187.
228. [228] Leblhuber, F., et al. Increased serum neopterin concentrations in patients with Alzheimer's disease. Clin. Chem. Lab. Med. 37 (1999), 429–431, 10.1515/CCLM.1999.070.
229. [229] Hull, M., Pasinetti, G.M., Aisen, P.S., Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 14 (2000), 228–230.
230. [230] Blasko, I., et al. Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin. J. Psychiatr. Res. 41 (2007), 694–701, 10.1016/j.jpsychires.2006.02.001.
231. [231] Hershkowitz, M., Adunsky, A., Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct dementia patients. Neurobiol. Aging 17 (1996), 865–868.
232. [232] Bazan, N.G., Colangelo, V., Lukiw, W.J., Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat. 68–69 (2002), 197–210.
233. [233] Wood, H., Alzheimer disease: prostaglandin E2 signalling is implicated in inflammation early in the Alzheimer disease course. Nat. Rev. Neurol., 2012, 8, 10.1038/nrneurol.2012.145.
234. [234] Combrinck, M., Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 77 (2006), 85–88, 10.1136/jnnp.2005.063131.
235. [235] Bagyinszky, E., Youn, Y.C., An, S.S., Kim, S.Y., Diagnostic methods and biomarkers for Alzheimer's disease. Toxicol. Environ. Heal. Sci. 6 (2014), 133–147.
236. [236] Galasko, D., Montine, T.J., Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark. Med 4 (2010), 27–36, 10.2217/bmm.09.89.
237. [237] Tan, Z.S., Seshadri, S., Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?. Alzheimers Res. Ther., 2, 2010, 10.1186/alzrt29.
238. [238] Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., Herrmann, N., A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68 (2010), 930–941, 10.1016/j.biopsych.2010.06.012.
239. [239] Zhang, F., Jiang, L., Neuroinflammation in Alzheimer's disease. Neuropsychiatr. Dis. Treat. 11 (2015), 243–256, 10.2147/NDT.S75546.
240. [240] Vasto, S., Candore, G., Duro, G., Lio, D., Grimaldi, M.P., Caruso, C., Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8 (2007), 1735–1745, 10.2217/14622416.8.12.1735.
241. [241] Birch, A.M., Katsouri, L., Sastre, M., Modulation of inflammation in transgenic models of Alzheimer's disease. J. Neuroinflammation, 11, 2014, 10.1186/1742-2094-11-25.
242. [242] Mecocci, P., Polidori, M.C., Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim. Biophys. Acta 1822 (2012), 631–638, 10.1016/j.bbadis.2011.10.006.
243. [243] Aliev, G., et al. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini-Rev. Med. Chem. 8 (2008), 1395–1406.
244. [244] Stankowska, D.L., Krishnamoorthy, V.R., Ellis, D.Z., Krishnamoorthy, R.R., Neuroprotective effects of curcumin on endothelin-1 mediated cell death in hippocampal neurons. Nutr. Neurosci., 2015, 10.1080/1028415X.2015.1119377.
245. [245] Zheng, C., Zhou, X.W., Wang, J.Z., The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl. Neurodegener., 5, 2016, 7, 10.1186/s40035-016-0054-4.
246. [246] Jha, M.K., et al. Diverse functional roles of lipocalin-2 in the central nervous system. Neurosci. Biobehav. Rev. 49 (2015), 135–156, 10.1016/j.neubiorev.2014.12.006.
247. [247] Suk, K., Lipocalin-2 as a therapeutic target for brain injury: an astrocentric perspective. Prog. Neurobiol. 144 (2016), 158–172, 10.1016/j.pneurobio.2016.08.001.
248. [248] Choi, J., Lee, H.W., Suk, K., Increased plasma levels of lipocalin 2 in mild cognitive impairment. J. Neurol. Sci. 305 (2011), 28–33, 10.1016/j.jns.2011.03.023 PMID: 21463871.